Bolt Metals Corp
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 100
- Market Cap
- -
- Website
- http://www.boltbio.com
- Introduction
Bolt Metals Corp is engaged in the acquisition and exploration of mineral exploration and evaluation assets in Indonesia. The company owns a nickel project named Cyclops located in Indonesia. It operates in a single reportable operating segment the Acquisition and exploration of exploration and evaluation assets located in Indonesia and Canada.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT06921837
- Locations
- 🇦🇺
AUS Site 2, Darlinghurst, New South Wales, Australia
🇦🇺AUS Site 1, Birtinya, Queensland, Australia
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
- Conditions
- Triple Negative Breast CancerColorectal CancerClear Cell Renal Cell CarcinomaMelanomaHead and Neck CancerOvarian CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT06052852
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Trial of BDC-1001 +/- Pertuzumab in Subjects with HER2-Positive Metastatic Breast Cancer
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05954143
- Locations
- 🇺🇸
City of Hope, Irvine, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Virginia Cancer Specialists, Arlington, Virginia, United States
A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors
- Conditions
- HER2-positive Colorectal CancerHER2-positive Solid TumorsHER2-positive Endometrial CancerHER2-positive Breast CancerHER2-positive Gastroesophageal Cancer
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT04278144
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States